David M Brown

Summary

Publications

  1. ncbi request reprint Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients
    David M Brown
    Vitreoretinal Consultants, Houston, Texas 77030, USA
    Am J Ophthalmol 144:627-37. 2007
  2. doi request reprint Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas 77030, USA
    Retina 33:23-34. 2013
  3. doi request reprint Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA
    Ophthalmology 120:349-54. 2013
  4. doi request reprint Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA
    Ophthalmology 118:1089-97. 2011
  5. ncbi request reprint Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas 77030, USA
    Ophthalmology 117:1124-1133.e1. 2010
  6. doi request reprint Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study
    David M Brown
    Retinal Consultants of Houston, Houston, Texas, USA
    Ophthalmology 118:1594-602. 2011
  7. doi request reprint Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
    David M Brown
    Vitreoretinal Consultants, Methodist Hospital, Houston, Texas 77030, USA
    Ophthalmology 116:57-65.e5. 2009
  8. ncbi request reprint Long-term stability of circumferential silicone sponge scleral buckling exoplants
    David M Brown
    The Methodist Hospital, Houston, Texas 77030, USA
    Retina 26:645-9. 2006
  9. ncbi request reprint Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    David M Brown
    Vitreoretinal Consultants, Methodist Hospital, Houston, TX 77030, USA
    N Engl J Med 355:1432-44. 2006
  10. doi request reprint SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results
    Charles C Wykoff
    Retina Consultants of Houston, The Methodist Hospital, Houston, TX 77030, USA
    Ophthalmic Surg Lasers Imaging Retina 44:121-6. 2013

Detail Information

Publications26

  1. ncbi request reprint Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients
    David M Brown
    Vitreoretinal Consultants, Houston, Texas 77030, USA
    Am J Ophthalmol 144:627-37. 2007
    ....
  2. doi request reprint Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas 77030, USA
    Retina 33:23-34. 2013
    ..To investigate if anatomical characteristics of eyes undergoing ranibizumab therapy were predictive of best-corrected visual acuity (BCVA) outcomes over 2 years...
  3. doi request reprint Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA
    Ophthalmology 120:349-54. 2013
    ....
  4. doi request reprint Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA
    Ophthalmology 118:1089-97. 2011
    ..To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular degeneration (AMD)...
  5. ncbi request reprint Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas 77030, USA
    Ophthalmology 117:1124-1133.e1. 2010
    ..To assess the efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO)...
  6. doi request reprint Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study
    David M Brown
    Retinal Consultants of Houston, Houston, Texas, USA
    Ophthalmology 118:1594-602. 2011
    ..Assess 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after branch retinal vein occlusion (BRVO)...
  7. doi request reprint Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
    David M Brown
    Vitreoretinal Consultants, Methodist Hospital, Houston, Texas 77030, USA
    Ophthalmology 116:57-65.e5. 2009
    ....
  8. ncbi request reprint Long-term stability of circumferential silicone sponge scleral buckling exoplants
    David M Brown
    The Methodist Hospital, Houston, Texas 77030, USA
    Retina 26:645-9. 2006
    ..This study was undertaken to assess the long-term stability of 360 degrees circumferentially placed 3 x 5 mm silicone sponge exoplants...
  9. ncbi request reprint Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    David M Brown
    Vitreoretinal Consultants, Methodist Hospital, Houston, TX 77030, USA
    N Engl J Med 355:1432-44. 2006
    ....
  10. doi request reprint SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results
    Charles C Wykoff
    Retina Consultants of Houston, The Methodist Hospital, Houston, TX 77030, USA
    Ophthalmic Surg Lasers Imaging Retina 44:121-6. 2013
    ..To assess durability of visual and anatomic gains with 2.0 mg ranibizumab in recalcitrant neovascular age-related macular degeneration (AMD)...
  11. doi request reprint Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, TX, USA
    Am J Ophthalmol 155:429-437.e7. 2013
    ..To evaluate intravitreal aflibercept injections (IAI; also called VEGF Trap-Eye) for patients with macular edema secondary to central retinal vein occlusion (CRVO)...
  12. doi request reprint Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity
    James C Major
    Retina Consultants of Houston, Weill Cornell Medical College and the Methodist Hospital, Houston, Texas
    Retina 34:48-54. 2014
    ....
  13. pmc Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
    Eric Chen
    Retina Consultants of Houston, The Methodist Hospital, Houston, TX, USA
    Clin Ophthalmol 4:1249-52. 2010
    ..The purpose of this study is to determine the efficacy of combining topical nepafenac with monthly intravitreal injections of ranibizumab or bevacizumab in the treatment of recalcitrant exudative macular degeneration...
  14. doi request reprint Endophthalmitis after intravitreal injection: the importance of viridans streptococci
    Eric Chen
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA
    Retina 31:1525-33. 2011
    ..To determine the rate of postinjection endophthalmitis and compare microbial etiology and outcomes in office-based injection-related endophthalmitis versus those acquired after operating room procedures...
  15. pmc Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign)
    Eric Chen
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA
    Clin Ophthalmol 4:1151-8. 2010
    ..Patients receiving HCQ were evaluated with spectral domain optical coherence tomography (SD OCT) to assess the feasibility of identifying HCQ retinopathy at an early stage...
  16. doi request reprint Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas
    Ophthalmology 120:2013-22. 2013
    ..To report 36-month outcomes of RIDE (NCT00473382) and RISE (NCT00473330), trials of ranibizumab in diabetic macular edema (DME)...
  17. pmc Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
    Eric Chen
    Retina Consultants of Houston, Texas, USA
    Clin Ophthalmol 4:1073-9. 2010
    ..This pilot study was designed to determine the threshold fluence dose of vPDT (the dose required to demonstrate an effect on choroidal perfusion) combined with ranibizumab...
  18. ncbi request reprint Selected clinical comparisons of spectral domain and time domain optical coherence tomography
    Damien M Luviano
    Greater Houston Retina Research Center, Vitreoretinal Consultants, Houston, Texas, USA
    Ophthalmic Surg Lasers Imaging 40:325-8. 2009
    ..In each case, the improved images provided by SD-OCT changed either the management of the patient or the counseling of their disease process...
  19. ncbi request reprint Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)
    Charles C Wykoff
    Retina Consultants of Houston, Weill Cornell Medical College, Houston Methodist Hospital, Houston, Texas, USA
    Br J Ophthalmol 98:951-5. 2014
    ..To determine the efficacy of 2.0 mg aflibercept in the management of patients with recalcitrant exudative age-related macular degeneration (AMD)...
  20. ncbi request reprint Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results
    Peter K Kaiser
    Cole Eye Institute, Cleveland, OH 44195, USA
    Am J Ophthalmol 144:850-857. 2007
    ....
  21. ncbi request reprint Ranibizumab for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    N Engl J Med 355:1419-31. 2006
    ..Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration...
  22. doi request reprint Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
    Carl D Regillo
    Retina Service, Wills Eye Institute, 840 Walnut Street, Philadelphia, PA 19107, USA
    Am J Ophthalmol 145:239-248. 2008
    ..To evaluate the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)...
  23. pmc Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema
    David J Browning
    Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL 33647, USA
    Ophthalmology 115:1366-71, 1371.e1. 2008
    ..To evaluate optical coherence tomography (OCT) measurements and methods of analysis of OCT data in studies of diabetic macular edema (DME)...
  24. doi request reprint Cystoid macular edema secondary to albumin-bound paclitaxel therapy
    Stacy V Smith
    Arch Ophthalmol 126:1605-6. 2008
  25. pmc Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema
    David J Browning
    Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL 33647, USA
    Ophthalmology 114:525-36. 2007
    ..To compare optical coherence tomography (OCT)-measured retinal thickness and visual acuity in eyes with diabetic macular edema (DME) both before and after macular laser photocoagulation...